<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467662</url>
  </required_header>
  <id_info>
    <org_study_id>376.hmo-ctil</org_study_id>
    <nct_id>NCT00467662</nct_id>
  </id_info>
  <brief_title>Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)</brief_title>
  <official_title>The Safety, Efficacy and Convenience of Use of the Natural Agent &quot;Superlysin Gel&quot; as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent cold sores - herpes simplex labialis (HSL) occurs in 20-40% of the US population&#xD;
      and patient seek treatment because of the discomfort and visibility of the lesion although it&#xD;
      is a self limiting disease. The purpose of this study is to check the safety, Efficacy and&#xD;
      convenience of Use of the Natural Agent &quot;Superlysin Gel&quot; as Treatment for Herpes Labialis in&#xD;
      Comparison to Acyclovir 5% and Docozanole 10%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      -Double blinded non-inferiority prospective parallel-group, intend to treat trial. Enrolment&#xD;
      of 75 patients (25 randomized for each group). - Approval of the Institutional Ethical Review&#xD;
      Board -&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      - Patient characteristics (selected) and historical information assessment including: Race,&#xD;
      average episode duration from patient history Duration of most recent previous episode Time&#xD;
      since last onset of oral-facial herpes simplex Time since first onset of oral-facial herpes&#xD;
      simplex Does patient experience localized prodrome?&#xD;
&#xD;
        -  Experiment duration; 5 to 10 days&#xD;
&#xD;
        -  4 visits (days 1, 3,6,10)&#xD;
&#xD;
        -  5 application /day for each derivative&#xD;
&#xD;
        -  Documentation Metric digital images of localized area signs at each visit Clinical&#xD;
           assessment of prodrome/erythema, papule, vesicle, ulcer, crust, or healed skin (with or&#xD;
           without residual erythema) Visual analogue scale (VAS) for subjective assessment of&#xD;
           pain, burning, itching or tingling at each visit&#xD;
&#xD;
        -  Calculation of primary efficacy end point (time to healing); from the date and time of&#xD;
           the initiation of therapy until the date and time of the clinic visit at which complete&#xD;
           resolution of all local signs and symptoms, i.e. the lesion had aborted or complete&#xD;
           healing had occurred (censored at day 10)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reducing healing process and duration of cold sores using superlysin gel</measure>
  </primary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Reccurent Herpes Labialis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 5%</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docosanol 10%</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Superlysine gel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age range (yrs) 18-70&#xD;
&#xD;
          -  Gender ; Males and females&#xD;
&#xD;
          -  Health status; immuno-competent&#xD;
&#xD;
          -  Clinical history of HSL with at least two recurrences during the past 12 months. The&#xD;
             most recent previous episode must have healed at least 14 days before screening.&#xD;
&#xD;
          -  Less than 12 hours after prodrome initiation (i.e. local erythema w/o blistering,&#xD;
             tingling and or burning sensation, soreness)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Mentally disabled&#xD;
&#xD;
          -  No intra-oral lesions, or lesions above the nostrils and below the chin&#xD;
&#xD;
          -  No topical steroid use and no systemic antiviral current treatments within 7 days&#xD;
             before the study&#xD;
&#xD;
          -  No known allergies to topical cosmetics&#xD;
&#xD;
          -  No use cosmetics on or around the mouth during the treatment period&#xD;
&#xD;
          -  No concomitant use of systemic corticosteroids or other drugs known to induce immune&#xD;
             stimulation or immune suppression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doron Aframian, DMD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Salivary Gland Clinic, Department of Oral Medicine The Hebrew University-Hadassah School of Dental Medicine Jerusalem, Israel P.O.B 12272, Zip code 91120</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doron J Aframian, DMD, PhD</last_name>
    <phone>0097226776151</phone>
    <email>Daframian@yahoo.com</email>
  </overall_contact>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2007</study_first_posted>
  <last_update_submitted>April 30, 2007</last_update_submitted>
  <last_update_submitted_qc>April 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Docosanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

